PDSB - PDS Biotechnology Corp (PDSB) - Clinical Progress Continues As 1Q22 Results Were Within Expectations

PDS Biotechnology Reported 1Q22. PDS Biotechnology reported a loss of $8.5 million or $(0.32) per share for 1Q22, consistent with our expectations. The company also gave updates on its clinical trials and pipeline products, and has two upcoming poster presentations scheduled to provide clinical data updates from PDS0101 trials in trials for HPV-associated cancers. Cash on hand at the end of the quarter was $58.9 million.PDS0101 Has Four Trials For HPV-Associated Cancer. The lead product is PDS0101, a cancer therapy that uses the Versamune technology to deliver the HPV16 antigen. There are four trials in progress that test the drug in HPV-associated cancers found in any tissue or location, and at different stages of disease, and in combination with other drugs. Two clinical updates are scheduled for the American Society of Clinical Oncology (ASCO) from June 3-7. Read More >>